Subscribe
flocu
flocu / iStockphoto.com
13 September 2017Americas

Teva sells Paragard contraceptive for $1.1bn

Medical device firm Cooper Companies has agreed to acquire the global rights to Teva’s Paragard intrauterine device (IUD) for $1.1 billion.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Teva and generics in SPC win against MSD
23 March 2017   The English High Court has ruled that a supplementary protection certificate owned by Merck Sharp & Dohme is invalid because it didn’t comply with European regulations.
Americas
Teva and Amneal lose patent battle against Mallinckrodt
10 October 2016   Ireland-based biopharmaceutical company Mallinckrodt and Endo, a US healthcare business, have won a patent case against Amneal and Teva.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

More on this story

Big Pharma
Teva and generics in SPC win against MSD
23 March 2017   The English High Court has ruled that a supplementary protection certificate owned by Merck Sharp & Dohme is invalid because it didn’t comply with European regulations.
Americas
Teva and Amneal lose patent battle against Mallinckrodt
10 October 2016   Ireland-based biopharmaceutical company Mallinckrodt and Endo, a US healthcare business, have won a patent case against Amneal and Teva.

More on this story

Big Pharma
Teva and generics in SPC win against MSD
23 March 2017   The English High Court has ruled that a supplementary protection certificate owned by Merck Sharp & Dohme is invalid because it didn’t comply with European regulations.
Americas
Teva and Amneal lose patent battle against Mallinckrodt
10 October 2016   Ireland-based biopharmaceutical company Mallinckrodt and Endo, a US healthcare business, have won a patent case against Amneal and Teva.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?